Two Approaches in Enhancing the Efficacy of Inferior Alveolar Nerve Block During Treatment of Mandibular First Permanent Molars With Symptomatic Irreversible Pulpitis

Evaluation of Two Approaches in Enhancing the Efficacy of Inferior Alveolar Nerve Block During Treatment of Mandibular First Permanent Molars With Symptomatic Irreversible Pulpitis: A Randomized Parallel Controlled Trial

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05427903

Enrollment

180

Registered

2022-06-22

Start date

2022-03-04

Completion date

2022-07-01

Last updated

2022-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Procedural

Brief summary

The study is designed as a randomized parallel controlled trial with three groups. Participants aged above 18 years with the first permanent molars with symptomatic signs of irreversible pulpitis will be randomly assigned into 3 groups. The first group (experimental group) will be injected with 4% articaine 1:100.000 epinephrine (inferior alveolar nerve block) will be anesthetized using 4% articaine 1:100.000 plus cryotherapy application, and the second group (experimental group) will be anaesthetised with IANB plus buccal infiltration. For the third group (control group), the mandibular molars will be anaesthetized using epinephrine using the inferior alveolar nerve block.

Interventions

PROCEDURECryotherapy

Ice packs application for 5 minutes after IANB injection

PROCEDUREBuccal local anesthetic infiltration using articaine 4% 1:100000 epinephrine

Buccal infiltration after IANB

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Patients aged above 18 years * Presence of at least one mandibular first permanent molar, with signs and symptoms of irreversible pulpititis

Exclusion criteria

* Participants with a history of taking medications that could interfere with the action of the anaesthetic solutions * Presence of paresthesia * Presence of psychological problems * Taking analgesics or other medications that would alter the inflammatory response of the pulp or provide analgesia 12 h pre-operatively

Design outcomes

Primary

Measure	Time frame	Description
Pain assessment	up to 24 hours	verbal rating scale (VRS) withh the following scores: Score 0: no pain, Score 1: mild pain, Score 2: moderate pain, and Score 3: severe pain.

Countries

Egypt

Contacts

Primary ContactAhmad Elheeny, PhD

ahmedelheeny@mu.edu.eg00201064257135

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026